A Semiparametric Bayesian Approach to Average by Pulak Ghosh & Gary L. Rosner
A Semiparametric Bayesian Approach to Average
Bioequivalence
Pulak Ghosh∗and Gary L. Rosner†‡
May 25, 2005
Summary
Bioequivalence assessment is an issue of great interest. Development of statistical
methods for assessing bioequivalence is an important area of research for statisti-
cians. Bioequivalence is usually determined based on the normal distribution. We
relax this assumption and develop a semiparametric mixed model for bioequiva-
lence data. The proposed method is quite ﬂexible and practically meaningful. Our
proposed method is based on a mixture normal distribution and a nonparametric
Bayesian approach using mixture of Dirichlet process prior. A numerical example
illustrates the use of our procedure.
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11 Introduction
Bioequivalence assessment has become an issue of great interest to the biopharmaceutical indus-
try during the last few decades, especially after it became evident that the marketed products
having the same amounts of the drug may exhibit marked diﬀerences in their therapeutic re-
sponses (Westlake, 1972, 1974 1979, 1981; Metzler, 1974). Nowadays, on the basis of simple
pharmacokinetic concepts and parameters, bioavailability and bioequivalence studies have been
established as acceptable surrogates for expensive, complicated and lengthy clinical trials. Such
trials are used worldwide to establish and ensure consistent product quality, as well as reliable
and therapeutically eﬀective performance of marketed dosage form. Three situations have thus
been deﬁned (Chow and Liu, 2000) in which bioequivalence studies are required (i) when the
proposed marketed dosage form is diﬀerent from that used in pivotal clinical trials, (ii) when
signiﬁcant changes are made in the manufacture of the marketed formulation, and (iii) when a
new generic formulation is tested against the innovator’s marketed product.
A bioequivalence study is an experiment to compare a test product (T) to a reference prod-
uct (R). Bioequivalence studies compare both the rate and extent of absorption of various drug
formulations with the innovator (reference) product on the basis that if two formulations ex-
hibit similar drug concentration-time proﬁles in the blood/plasma, they should exhibit similar
therapeutic eﬀects. For an unapproved generic dosage form to be marketed and accepted as
therapeutically eﬀective in relation to the innovator product, it must have established bioe-
quivalence with the innovator product, in vivo. The determination of bioequivalence is, thus,
very important in the pharmaceutical industry because regulatory agencies like the U.S. Food
and Drug Administration (FDA) allow a generic drug to be marketed only if its manufacturer
can demonstrate that the generic product is bioequivalent to the innovator product. According
to FDA regulations (1999, 2001, 2002), a valid statistical evaluation of bioequivalence trial is
essential in order to guarantee the safety and eﬃcacy of the generic drug products.
2Bioequivalence studies usually proceed by administering dosages to subjects and measuring
the concentration of the drug in the blood just before and at set times after its administration.
These concentration-by-time measurements are often connected with a polygonal curve and
measurements of the drug’s pharmacokinetics, like AUC (area under curve), Cmax (maximum
concentration) and Tmax (time to maximum concentartion) are calculated. For statistical anal-
ysis, these measures are taken as the response variables. Until recently, regulatory guidelines
have suggested the consideration of average bioequivalence (ABE) (Mandallaz et. al., 1981;
Berger et. al., 1996). ABE requires equivalence between the population means of the pharma-
cokinetic measurements for the reference and test formulations. Over the past few years, the
FDA (1999, 2002) supplemented ABE with two more criteria, viz., population bioequivalence
(PBE) and individual bioequivalence (IBE)., These new criteria have also been the subject of
dispute, however, and ABE still remains the main criterion for assessing bioequivalence between
two formulations. The main advantage of ABE is its easier interpretation for the intended au-
diences, including regulators, prescribing physicians, pharmacists, and patients. The criterion
of ABE has also found potential applications in several other areas such as, psychology (Rogers
et. al., 1993), chemistry (Roy, 1997), and environmental statistics (McBride, 1998).
In this paper, we take a Bayesian approach to assessing ABE. The key advantage of using a
Bayesian approach for bioequivalence trials is the ability of the Bayesian inferential paradigm
to incorporate background information thought pertinent to the clinical question being asked
(Ghosh and Khattree, 2003). Breslow (1990) argued that bioequivalence is a perfectly natural
concept to be subjected to Bayesian analysis. Several authors have also advocated a Bayesian
approach to average bioequivalence inference (Rodda and Davis, 1980; Mandallaz and Mau,
1981; Selwyn et. al., 1981; Grieve, 1985; Racine-Poon et. al., 1987). The main idea of all
the above methods is to ﬁnd the posterior distribution of the parameter of interest based on
non-informative prior distributions for the parameters. Recently, Ghosh and Khattree (2003)
used an intrinsic Bayes factor approach to test ABE.
3All of the existing literature on ABE, however, relies heavily on a normality assumption.
The normality assumption in a bioequivalence trial may not always be true, however, and
the inference can be misleading. Chow and Tse (1990) and Bolton (1991) discussed that
the normality assumption in a bioequivalence trial may lack robustness against outliers and
skewness. Usually a bioequivalence trial is conducted with a small number of healthy subjects,
and it is not always possible to validate the normality assumption. Instead of following a normal
distribution, the data from a bioequivalence trial may have a mixture of normal distributions
(e.g., diverse populations, such as from pharmacogenetic variation), a distribution with heavier
tails, or some other distribution which can not be easily speciﬁed. Thus, it is of practical interest
to develop statistical models in ABE that move beyond the traditional parametric model.
This paper addresses robust inference in bioequivalence studies by developing a robust Bayesian
analysis to assess ABE. We show how a robust Bayesian model can lead to better insights in
a bioequivalence study. Our method extends existing methods by allowing for possible hetero-
geneity of the subjects who are participating in the study. In our analysis, we use two diﬀerent
approaches to model the random subject eﬀect. First we suggest modeling random subject
eﬀects using a mixture of two normal distribution. Mixture distributions can characterize
diﬀerent distributional shapes and can describe diﬀerent features of the bioequivalence data.
We also propose a Bayesian nonparametric methods using a Dirichlet process (DP) mixture
(Ferguson, 1973; Antoniak, 1974; Escobar, 1994; MacEachern, 1994; Escobar and West, 1995)
to relax the distributional assumption and to accommodate possible population heterogeneity.
DP mixture models are, by far, the most widely used nonparametric Bayesian model, mainly
because one can easily obtain posterior estimates using standard MCMC approaches, such as
Gibbs sampling (Gilks et al., 1996; MacEachern and M¨ uller, 1998).
The plan of the paper is as follows. Section 2 introduces a parametric random eﬀects model
for average bioequivalence (ABE) trial which assumes a normal distribution for the random
eﬀects. In section 3 we present the semiparametric extension of the model which allows for a
4wide range of distributions for the random eﬀects. In section 4, we describe the data and the
results of the empirical analysis are presented. Section 5 draws conclusions and provides an
outlook on future research.
2 Model
In most bioequivalence trials, a test formulation is compared with the innovator reference for-
mulation in a group of normal, healthy subjects, as recommended by the US FDA (2001, 2002).
Each participant receives the treatments alternatively in a crossover study. The most commonly
used statistical design for comparing average bioequivalence between a test formulation (T) and
a reference formulation (R) of a drug is a two-sequence, two-period, crossover design (Chow
and Liu, 2000). We refer to this design as a standard 2 × 2 crossover design. The following
statistical model is usually considered for a 2 × 2 crossover design.
yijk = µi,k + Si + Pk + δij + eijk (1)
In this model, we consider yijk to be the logarithm of response in the ith sequence from the kth
period for the jth subject, (i = 1,2;j = 1,2,    ,ni;k = 1,2). We use the logarithm, because
often the response measures in a bioequivalence study follow a lognormal distribution, due to
skewness. Furthermore, µi,k is the direct eﬀect of the formulation in the ith sequence that is
administered at the kth period, Si is the ﬁxed eﬀect of the ith sequence (S1 + S2 = 0), Pk is
the ﬁxed eﬀect of period k (P1 + P2 = 0), δij is the random eﬀect of the jth subject in the ith
sequence, and eijk is the within subject random error in observing yijk.
If we assume, without loss of generality, that the ﬁrst period in the ﬁrst sequence is the
5reference formulation (R), then
µi,k =

 
 
µR if k = i
µT if k  = i.
;µR + µT = 0.
The random variables δij are assumed to be i.i.d normal with mean 0 and variance σ2. The
eijk are i.i.d normal with mean 0 and variance σ2
l , where l = R if k = i and l = T otherwise.
We assume that δij and eijk are mutually independent.
2.1 Average Bioequivalence Criteria
Two drugs are called average bioequivalent if the population means of the drug-speciﬁc AUCs
are suﬃciently close. In statistical terms, the problem of ABE is to decide if the diﬀerence of
two parameters ∆ = µT −µR is close to zero. Formally, the hypothesis of average bioequivalence
is formulated as:
H0 : ∆ ≤ θL or ∆ ≥ θU vs. Ha : θL < ∆ < θU, (2)
where the lower and upper tolerance limits θL and θU are known constants speciﬁed by the
FDA. The limits θL = log(0.8) and θU = log(1.25) are widely accepted by drug authorities for
testing bioequivalence in terms of AUCs.
The hypothesis testing set up in (2) is the reverse of the ordinary view of testing. Whereas a
null hypothesis is usually a hypothesis of equivalence, we now consider the lack of equivalence
the null hypothesis that we seek to disprove. This formulation makes a great deal of sense
for bioequivalence trials. Here the type I error is the probability of declaring the drugs to
be bioequivalent when they are not. Therefore, by setting up the hypothesis as in (2), the
consumer’s risk is protected. Once the consumer’s risk is restricted to, say, a level 5% error,
the agency leaves the pharmaceutical industry to determine the extent of manufacturer’s risk
via the type II error.
6In a Bayesian hypothesis test, the construction might be based on the posterior probabilities
of the hypothesis. In general, the hypothesis with higher posterior probability is accepted.
Thus, in our case, if the posterior probability of H1 is greater than 0.5 then ABE will be
established. One could also incorporate utilities or losses and apply decision-theoretic criteria
to make decisions about ABE. We do not follow that extension in this paper.
3 Robust Distribution of the Random Eﬀect
The most common choice for the distribution of the random eﬀect δij in the model for a crossover
design in (1) is the normal distribution. Almost all of the inferential procedures currently used
for assessing ABE are based on this assumption. The choice of the normal distribution for the
random eﬀect, however, is quite arbitrary. It may well happen that the normal distribution
does not correctly ﬁt the data at hand, for example if the data are skewed, contain outliers,
or consist of diverse populations. This section considers a model for the random eﬀects that
generalizes the normality assumption of δij to include an entire class of distributions. The aim
of this generalization is to protect the inference from bias resulting from incorrect speciﬁcation
of the random eﬀect distribution. This generalization has the potential to make the inference
robust to departures from a normal distribution while still having good performance if the actual
distribution is normal. The motivation is to model the random eﬀects by ﬁtting a mixture of
parametric distributions or by considering ﬂexible non-parametric distributions. We consider
these two possibilities in the following two subsections.
3.1 Normal Mixture Distribution
A viable alternative to a single normal distribution for the random eﬀect is a mixture structure
with several normal components for the δij. See West (1992) and Robert (1996) for details
7on mixture modeling. Verbeke and Lesaﬀre (1996) discussed the advantage of using a mixture
model in linear mixed eﬀects models. We follow Verbeke and Lesaﬀre (1996) and assume a two-
component mixture. The mixture model proposed in equations (3-6) takes place at a latent
observation level, since we only observe the data yijk. Formally we assume the following prior
model speciﬁcation:
δij ∼ πN(µ1,σ
2
1) + (1 − π)N(µ2,σ
2
2) (3)
µf ∼ N(0,σ
2
µ); f = 1,2 (4)
σ
2
f ∼ IG(a,b) (5)
π ∼ Beta(aπ,bπ) (6)
The hyperparameters (σ2
µ,a,b,aπ,bπ) are assumed to be known. We impose an ordering con-
straint on the means (µj1 < µj2) (Roeder and Wasserman, 1996) to avoid well-recognized
identiﬁability problems. Observe that in the formulation (3-6), the number of mixture compo-
nents is assumed to be known, yielding a parametric mixture model. We carry out posterior
inference using Markov chain Monte Carlo (MCMC) methods, which have appeared recently
in the literature for analyzing data with mixture models (see for example. Diebolt and Robert,
1994; Roeder and Wasserman, 1997). The ﬂexibility of a prior mixture model is its ability to
accommodate a large number of true distributional forms. Unless the information feeding up
from the data is incredibly strong and the true distributional form of the random eﬀects is such
that it cannot be represented by a mixture of two normals (e.g., if it is tri-modal), it is unlikely
that this random eﬀect distribution would be deemed inappropriate. Because of the ﬂexibility
allowed by the Bayesian approach and the easy Gibbs sampling simulation techniques, inference
on this extension is possible using WinBUGS (2003) (http://www.mrc-bsu.cam.ac.uk/bugs).
We provide some of the WinBUGS program in an appendix.
83.2 Mixture of Dirichlet Process
A further and more ﬂexible extension for specifying the random eﬀects distribution, one that
goes beyond a ﬁnite mixture, is a Bayesian nonparametrics approach (Ferguson, 1973; Dey,
M¨ uller, & Sinha, 1997; Ghosh & Ramamoorthi, 2003). In this section, we model δij using a
Dirichlet process mixture prior that is given by:
δij ∼ N(µj,σ
2
δ) (7)
µj ∼ G (8)
G ∼ DP(αG0) (9)
G0 ∼ N(0,σ
2
G) (10)
σ
2
δ ∼ IG(c,d) (11)
The above prior is a mixture of normals with respect to a mixing measure G. The mixing
measure, G is a Dirichlet process. The parameters of a Dirichlet process are G0 a probability
measure, and α, a positive scalar assigning mass to the real line. The parameter G0 is often
called the base measure and is a distribution that approximates the true nonparametric shape
of G. The concentration parameter α reﬂects our prior belief about how similar G is to G0.
Large values of α lead to a G that is very close to G0. Small values of α allow G to deviate
more from G0 and put most of its probability mass on just a few atoms. The prior for α is
discussed in the next section. The hyperparameters (σ2
G, c, d) are assumed to be known.
3.2.1 A Finite Approximation
The above representation provides a formal deﬁnition of the Dirichlet process mixture prior.
There are several ways to implement a DP mixture prior. Recent research has focussed on using
the constructive deﬁnition of the Dirichlet process to produce MCMC algorithms (Ishwaran and
James, 2002; Ishwaran and Zarepour, 2000, 2002; Ishwaran and James, 2001). Following Sethu-
9raman (1994), one way to generate the DP mixture prior is to regard the inﬁnite dimensional
parameter G as an inﬁnite mixture. Thus, the Dirichlet process DP(αG0) can be written as,
G =
∞  
l=1
vlδZl = V1δZ1 +
∞  
l=2
(1 − V1)(1 − V2)   (1 − Vl−1)VlδZl, (12)
where V1,V2,    are i.i.d. Beta(1,α) random variables. Since the inﬁnite series (12) is almost
surely convergent, as l increases the random vectors (Vl,Zl) will have diminishing eﬀect on the
prior distribution and thus on the posterior distribution of δij. Thus, an approximation to the
Dirichlet process can be obtained by truncating the higher order terms in the stick-breaking
representations (12). This results in an approximating random probability measure (Choudhuri,
Ghosal and Roy, 2004; Ohlssen, 2005) of the form
G =
L  
l=1
vlδZl = V1δZ1 +
L  
l=2
(1 − V1)(1 − V2)   (1 − Vl−1)VlδZl (13)
where V1,V2,    ,VL−1 are i.i.d. Beta(1,α) random variables, and VL is set to one to ensure
that the random weights sum to unity.
The ﬁnite approximation (13) for DP can be used in WinBUGS to implement the Gibbs
sampling for ﬁtting a DP mixture model. This can be done by introducing latent variables
J = (J1,J2,    ,Jn) that indicate group membership for the unobserved variables µj, along
with a probability vector w = (w1,w2,    ,wL)T. Thus, model (7-11) can be written as:
10δij ∼ N(µJj,σ
2
δ) (14)
Jj|w ∼ Multinomial({1,2,    ,L},w) (15)
µl ∼ G, l = 1,2,    ,L (16)
G ∼ DP(αG0) (17)
G0 ∼ N(0,σ
2
G) (18)
w ∼ Dirichlet(
α
L
,
α
L
,    ,
α
L
) (19)
σ
2
δ ∼ IG(c,d) (20)
Note that the value of L in (13) is chosen to control the size of the tail probability
∞  
k=L+1
vk
The truncation point L needs to be chosen appropriately. The eﬀect of truncation on the
distribution of functionals of a Dirichlet process has been studied by Muliere and Tardella
(1998), Ishwaran and Zarepour (2002), and Ohlssen, 2005. Ishwaran and Zarepour (2002)
suggested L =
√
n for large n and L = n for small n. Since there is a linear relationship
between α and L, we adopt a uniform prior for α.
3.3 Prior Distribution
Parameters in model (1) are µ, S1 = −S2, P1 = −P2, FR = −FT, σ2
T, σ2
R, and α. For simplicity
we assume S = S1, P = −P1, F = FR. To complete the Bayesian speciﬁcation of the model,
we assign weakly informative priors to the unknown ﬁxed eﬀect parameters. Speciﬁcally, we
use conjugate prior for overall mean, µ ∼ N(µ0,σ2
µ), sequence eﬀect S ∼ N(S0,σ2
s), and period
eﬀect, P ∼ N(P0,σ2
P). For the error variance, we specify, σ2
l ∼ IG(al,bl),l = R,T, where
11IG(al,bl) denotes the inverse gamma distribution with shape parameter al and scale parameter
bl. The hyperparameters (σ2
µ, c, d, µ0, S0, σ2
s, P0, σ2
P, aR, aT, bR, bT) are assumed to be known.
3.4 Gibbs Sampling
The posterior distributions are analytically intractable and thus computations are done via
Monte Carlo approximations with the help of the MCMC method. The Gibbs sampler is
probably the most widely used MCMC method and is implemented in the software package
WinBUGS (2003). In general, MCMC works by drawing samples from distributions that converge
to the correct posterior distribution of the parameters. In Gibbs sampling, one draws samples
from the conditional posterior distributions of univariate parameters given the most recent
draws of the other parameters. Thus, what is required for the Gibbs sampler to work is
the ability to sample from the full conditional posterior distribution of the parameters. The
conditional distribution of all the parameters are obtained from the joint distribution of all the
parameters. We skip the explicit expression of the conditional distribution as Bugs calculates
the conditional distribution automatically. The method proposed in section (3.2) can also be
implemented in WinBUGS, since it is based on a ﬁnite mixture model. The main code is available
from the authors on request.
4 Data analysis
We illustrate the usefulness of the above methods by analyzing a real data set (Bradstreet,
1994) in this section.
124.1 Illustration
A two-by-two crossover study randomized twenty-six healthy male subjects to one of two treat-
ment sequences. The objective of the trial was to determine if the pharmacokinetic charac-
teristics of one 40 mg capsule of a drug made by Company A are the same as the concurrent
administration of two 20 mg capsules of the same drug made by Company B. The two treatment
sequences were either treatment A in the ﬁrst period followed by treatment B in the second
period or vice versa. A ﬁve-day or seven-day washout period separated the treatment periods.
The pharmacokinetic parameter AUC was calculated for each subject in each treatment period
from drug levels assayed from plasma samples taken at 0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, and8
hours post dose. The data is skewed and include a few outliers. See the histogram plots (Fig
1). The ﬁrst row of panels in ﬁgure 1 shows histograms of the period diﬀerences in the ﬁrst
sequence of the log transformed data. There is an outlier in both sequences. The second and
third row of ﬁgure 1 gives the exploratory plots for the treatment eﬀects, assuming no period
diﬀerences. The histograms indicates strong skewness in the data.
For the Bayesian analysis, we choose relatively diﬀuse priors. Speciﬁcally, throughout we
assume independent diﬀuse prior distribution N(0,103) for the parameters µ, S, P and assume
a weakly informative gamma prior distribution Γ(0.01,0.01) for the σ
−2
l .
For the mixture model (6), we assume N(0,102) for µ1 and µ2. In the case of higher com-
ponents of mixtures, a lower limit is set by the previous component of the mixture to avoid
identiﬁability problems. A Beta(1,1) prior is assumed for the mixing probability π and a
inverse-gamma (0.01,0.01) prior is assumed for σ2
1, σ2
2.
For the DP model (11), we assume G0 ∼ N(0,1000). A Uniform(0.5,4) covers a suﬃciently
wide range of values of α. The upper bound 4 is essentially arbitrary and some sensitivity
analysis on this may be useful. We tried various values of L and found that L = 30 works very
well. With 26 subjects in this data set, a truncation point 30 is suﬃciently high.
13The initial values for the ﬁxed parameters were selected by starting with the prior mean and
covering ±3 standard deviations. The initial values for the precision were arbitrarily selected.
In the analysis, we used 5000 burn-in iterations and 10,000 updates. The posterior estimates
of the parameters are presented in Table 1.
The estimates of the parameters across models agree broadly. In Table 1 we present the
posterior means. The treatment eﬀect is quite high in all the models, and it is signiﬁcant,
in the sense that the 95% credible interval does not contain zero. The negative estimates for
the sequence shows that the AUC at the second sequence seems larger than that at the ﬁrst
sequence. Negative estimates for the period eﬀect bear a similar interpretation. The variance
estimates for formulation B are greater than the corresponding estimates for formulation A in
all the models.
The Bayesian hypothesis test requires calculating the posterior probability of the hypotheses
described in (2). Thus, the posterior probability of average bioequivalence is computed using
the following equation:
P[ABE|data] = Pr[log(0.8) < µT − µR < log(1.25)|Data]
∼ =
1
m
m  
p=1
I[log(0.8) < µTp − µRp < log(1.25)]
where (µTp−µRP : p = 1,    ,m) is a sample from the observed posterior density of (µT −µR),
I(.) denotes the indicator function, and m = 10,000 is the number of iterations. If the posterior
probability deﬁned by the above equation is greater than 0.5, then average bioequivalence is
accepted. In Table 1, PABE is the posterior probability of ABE. ABE got rejected in all the
models since the posterior probability of ABE is less than 0.5. We note that the frequentist
threshold of 0.05 plays no role in interpreting posterior probabilities and we think the relevant
threshold is 0.5, suggesting that one should retain the hypothesis with the higher posterior
probability.
Rejection of ABE can be described by the high diﬀerence between the two treatments. Note,
14however, that the treatment diﬀerence reduces from the normal model to the Dirichlet model.
This happens because the eﬀect of outliers and skewness of the data reduces in the Dirichlet
model. Thus, the posterior probability of ABE also increases in the Dirichlet model and in
the mixture model compared with the normal model. This example thus clearly indicates the
usefulness of the mixture model, especially when the bioequivalence data are skewed and contain
outliers. The advantage of MDP model can also be justiﬁed from the residual plot in ﬁgure 2.
Residual plots form MDP model has a better behavior.
We compare the three models informally by computing the eﬀective number of parameters
pD and the deviance information criterion (DIC) as presented by Spiegelhalter et. al. (2002).
DIC can be implemented in WinBUGS and can be used to compare complex models. Large
diﬀerences in the criterion can be attributed to real predictive diﬀerences in the models. The
smaller the DIC the better the ﬁt, and a diﬀerence larger than 10 is overwhelming evidence in
favor of the better model (Burnham and Anderson, 2002).
Using DIC values in Table 2, we see that the MDP model gives improved model ﬁt over the
other two models. Spiegelhalter et. al. (2002) mention that pD roughly indicates the number
of parameters in the model. We see that DP model has maximum pD.
5 Conclusion
We have provided an easily implemented robust Bayesian model for studying the eﬀect of an
assumption of normality for the random eﬀects’ distribution in bioequivalence trials. Our model
aﬀords the ﬂexible use of informative priors. The ﬂexibility stems from the fact that it allows
for accommodation of the uncertainty in the distribution. The method yields ﬂexible data-
driven inference for bioequivalence. We have discussed how such inference can be obtained
and illustrated our method with an example. We found that the models with normal and two-
component mixture-of-normal distributions give quite similar results and, as expected, diﬀer
15from the results of the DP model.
We have illustrated our method of analysis in the context of a single parameter in the 2 × 2
crossover design with an equal number of subjects in each sequence and no dropouts. In
practice, our Bayesian method could be extended to more parameters and to other criteria,
such as individual bioequivalence. Such extensions are an area of ongoing research.
16APPENDIX: Implementation Using WinBUGS
We describe the MDP prior WinBUGS code to implement the methods described in this paper.
The full code is available from the authors upon request.
* T denotes the treatment eﬀect
* S denotes the sequence eﬀect
* P denotes the period eﬀect
* delta[g[i]] denotes random subject eﬀect
*g[i] is a variable that assigns a common subject number to each set of two observations taken
from the same subject
Model
{
2 × 2 crossover design
for ( i in 1:N)
{
y[i]∼ dnorm(mu[i],tau)
mu[i]<-T*x[i,1]+S*x[i,2]+P*x[i,3]+delta[g[i]]
}
tau∼dgamma(0.001,0.001)
MDP model distribution of random eﬀect
for (j in 1:K)
{
17delta[j]∼ dnorm(beta[group[i]],tau1)
group[i]∼ dcat(p[])
}
* Constructive DPP
p[1]<-r[1]
for (j in 2:L)
{
p[j]<-r[j]*(1-r[j-1])*p[j-1]/r[j-1]
}
p.sum<-sum(p[])
for (j in 1:L)
{
beta[j]∼dnorm (0,tau2)
r[j]∼dbeta(1,alpha)
* scaling to ensure sum to 1
pi[j]<-p[j]/p.sum
}
alpha∼dunif(0.5,4)
a∼ dnorm(0,0.001)
tau1 ∼ dgamma(0.001,0.001)
tau2 ∼ dgamma (0.001,0.001)
}
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23Table 1: Posterior Mean of the Parameters.
Parameter Normal Model Mixture Model Dirichlet Model
Sequence -0.1919 -0.1293 -0.2251
Period -0.08439 -0.1512 -0.03874
Treatment 1.942 1.3 1.07
σ2
eA 0.2575 0.2561 0.339
σ2
eB 0.6515 0.6526 0.6858
PABE 0.131 0.3375 0.435
Table 2: Eﬀective number of parameters, pD and DIC for the three ﬁtted models
for the ﬁrst data.
pD DIC
Normal Model 9.393 58.410
Mixture Normal Model 11.261 50.790
DP Model 12.811 45.063
24-0.5 0.0 0.5 1.0
0
1
2
3
4
Period diffrences (sequence 1)
F
r
e
q
u
e
n
c
y
6 7 8 9
0
2
4
6
8
Formulation A
F
r
e
q
u
e
n
c
y
6 7 8 9
0
2
4
6
8
Formulation B
F
r
e
q
u
e
n
c
y
Figure 1: Histogram of Period diﬀerences and treatment formulation
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Figure 2: Residual plots
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